Global eye-health company making contact lenses, eye surgery devices and eye-care/pharmaceutical products, spun off from Bausch Health.
Global eye-health company making contact lenses, eye surgery devices and eye-care/pharmaceutical products, spun off from Bausch Health.
Is the same business as the New York line, listed on both exchanges. Contact lenses and eye-health products are repeat purchases, while surgical products, cataract equipment, are sold to clinics and hospitals. Bausch Health remains its controlling shareholder after the 2022 float.
In one line: A dedicated eye-care peer to Alcon/CooperCompanies.
Moat: narrow (brand, scale, regulatory licence). Long-established Bausch + Lomb brand and broad regulatory approvals across contact lens and surgical device lines.
Headquarters: Vaughan, Canada / Bridgewater, New Jersey · Founded: 1853 · Employees: 13,000
Size Bausch + Lomb (BLCO.TO) is a Canada Health Care company (Medical Specialties) with a market value of $7.41B, the 89th largest of 405 Canada companies the cockpit tracks. Shares closed at C$30.03 on 18 Nov 2026.
Performance Over six months the shares gained 35.2%, against +28.4% for the median peer and +1.1% for the Canada market (cap-weighted) — 10th highest of 21 in its peer set.
Growth Revenue grew 11.3% over the last twelve months (peer median +3.2%); the operating margin is 9.4% (peer median 16.9%).
Valuation It trades at 18.3× forward earnings against a peer median of 21.0× (6th cheapest of 21).
Price implies For today's price to make sense, revenue must grow about 12% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.0 points below its cost of capital (6.4% WACC).
Credit Bausch + Lomb has 1 bond outstanding ($1.40B), rated B by the agencies and trading like B at a weighted spread of 397 bp.
Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | C$7.71B | C$7.00B | C$6.89B | C$5.50B | C$5.11B |
| Revenue growth | — | +2% | +25% | +8% | — |
| Gross profit | C$4.50B | C$3.84B | C$3.79B | C$3.00B | C$2.72B |
| EBITDA | C$1.30B | C$836M | C$924M | C$777M | C$812M |
| Net income | -C$158M | -C$494M | -C$456M | -C$345M | C$8.13M |
| Free cash flow | C$359M | -C$90.6M | -C$84.9M | -C$262M | C$230M |
| Capital expenditure | C$422M | C$479M | C$419M | C$240M | C$298M |
| Total debt | C$7.25B | C$7.20B | C$7.10B | C$6.20B | C$3.46B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Bausch + Lomb BLCO.TO | $7.41B | +35% | +11% | 9% | 18.3× | 12.0% |
| Alcon ALC.SW | $36.9B | +18% | +1% | 12% | 21.5× | 12.2% |
| Cooper Companies (The) COO | $11.6B | -2% | +5% | 19% | 13.4× | 9.4% |
| Johnson & Johnson JNJ | $656B | +20% | +8% | 26% | 24.2× | 3.7% |
| Carl Zeiss Meditec AFX.DE | $3.17B | +22% | 0% | 8% | 24.4× | 12.5% |
| Hoya 7741.T | $49.0B | -16% | +13% | 32% | 27.7× | 14.1% |
| Menicon 7780.T | $944M | +26% | +6% | 9% | 20.9× | n/a |
| Santen Pharmaceutical 4536.T | $4.14B | +10% | +2% | 16% | 16.7× | -5.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BLCO.TO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +26.5% | +8.5% | highest of 21 |
| 6-month return | +35.2% | +28.4% | 10th highest of 21 |
| Distance from 52-week high | -2.0% | -7.2% | 4th highest of 21 |
| Revenue growth (TTM) | +11.3% | +3.2% | 6th highest of 21 |
| Operating margin | 9.4% | 16.9% | 2nd lowest of 21 |
| Forward P/E | 18.3× | 21.0× | 6th cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | 12.0% | 10.6% | 9th most demanding of 20 |
| Growth delivered (Del g) | +10.0% | +9.3% | 9th highest of 20 |
| Hurdle (Req g minus delivered) | +2.0 pp | +1.8 pp | 10th most demanding of 20 |
| ROIC minus cost of capital | -3.0 pp | +3.4 pp | 5th lowest of 21 |
| EV / EBITDA | 13.3× | 16.0× | 5th cheapest of 19 |
| Net debt / EBITDA | 5.0× | 0.8× | most indebted of 19 |
| Bond spread | 397 bp | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Bausch + Lomb BLCO.TO | Canada | $7.41B | +35% | +11% | 9% | 18.3× | 12.0% | +10.0% |
| Getinge GETI-B.ST | Sweden | $7.45B | +40% | -4% | 14% | 21.1× | 5.0% | +3.2% |
| Shenzhen New Industries Biomedical Engineering 300832.SZ | China | $7.50B | +21% | +7% | 43% | 26.9× | 2.9% | +15.7% |
| Asahi Intecc 7747.T | Japan | $7.09B | +24% | +23% | 32% | 29.7× | 15.1% | +18.8% |
| Ypsomed YPSN.SW | Switzerland | $6.83B | +27% | -13% | 30% | 31.7× | n/a | n/a |
| Sysmex 6869.T | Japan | $8.06B | +58% | +8% | 13% | 32.0× | 4.4% | +10.4% |
| ConvaTec CTEC.L | United Kingdom | $6.78B | +37% | +2% | 16% | 17.7× | 17.2% | +4.6% |
| Shimadzu 7701.T | Japan | $8.14B | +24% | +8% | 14% | 21.0× | 8.3% | +7.3% |
| Cochlear COH.AX | Australia | $6.72B | +58% | -1% | 13% | 29.1× | 23.9% | +9.3% |
| Lantheus LNTH | United States | $6.67B | +6% | +2% | 19% | 15.5× | 0.4% | +35.3% |
| Teleflex TFX | United States | $6.58B | +23% | -29% | 12% | 16.7× | 16.5% | -4.7% |
| APT Medical 688617.SS | China | $6.06B | +23% | +28% | 37% | 38.6× | 9.0% | +40.1% |
| Globus Medical GMED | United States | $9.34B | -16% | +13% | 23% | 13.7× | 4.6% | +30.1% |
| Bruker BRKR | United States | $9.66B | +43% | +2% | 10% | 27.0× | 25.4% | +11.6% |
| Insulet PODD | United States | $9.71B | -11% | +26% | 18% | 18.6× | 10.6% | +24.5% |
| Haemonetics HAE | United States | $5.59B | +106% | +4% | 19% | 20.7× | 10.9% | +8.9% |
| Bio-Rad Laboratories BIO | United States | $10.1B | +29% | +1% | 9% | 34.6× | 26.0% | +0.3% |
| Qiagen QGEN | United States | $10.2B | +41% | +2% | 25% | 19.5× | 8.6% | +2.2% |
| Demant A/S DEMANT.CO | Denmark | $10.4B | +39% | +10% | 18% | 23.2× | 5.8% | +9.8% |
| Avantor AVTR | United States | $10.4B | +95% | +1% | 8% | 17.5× | 16.4% | +0.5% |
| LivaNova LIVN | United States | $5.21B | +28% | +12% | 15% | 20.9× | 14.2% | +8.2% |
Bausch + Lomb has 1 bond outstanding with $1.40B face value. The agencies rate it B; its bonds trade like B. Weighted yield 8.71%, a spread of 397 bp over government bonds.